In summary, this phase 2 clinical trial demonstrates for the first time that the combination of the EGFR/CD3 bispecific antibody SMET12, toripalimab, and chemotherapy exhibits a favorable safety profile in advanced NSCLC patients expressing EGFR protein, and demonstrates promising efficacy in EGFR-mutated advanced NSCLC patients with acquired resistance to TKIs. Here, EGFR is linked to non-small cell lung carcinoma.